ClinicalTrials.gg
CompletedNCT00091442Updated Apr 21, 2014Results posted

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

A Phase 3 interventional study of Docetaxel and DOXIL in Breast Cancer, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 151 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.

Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
751
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
Largest of 66
751 · median 57
Started
2004
with 1 other
Phase 3
10 of 67
2 open now
Registered
5th of 67
by date
Lead sponsor
2 of 67
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one has the largest enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 5th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.

Read the detailed description

This is a randomized (the study medication is assigned by a random order), active control (study medication will be compared with available standard care of treatment), parallel-group (each treatment group will be treated simultaneously at the same time and each participant only receives one treatment regimen as assigned), open-label (both the investigator and the participant know the intervention received by the participant), multicenter study designed to determine if women with locally advanced or metastatic breast cancer, who were previously treated with prior anthracycline therapy in the neoadjuvant (administration of treatment before surgery) or adjuvant setting (administration of treatment after surgery), and who also had a disease-free interval of at least 12 months since the end of their last cytotoxic therapy, would benefit from the addition of DOXIL to docetaxel therapy. Approximately 751 participants will be randomly assigned to either receive docetaxel monotherapy or DOXIL in combination with docetaxel therapy. Treatment is to continue until disease progression or the occurrence of unacceptable treatment related toxicity. Safety evaluations will include assessments of adverse events which will be recorded from the first study related procedure until 30 days after the last dose of medication; clinical laboratory tests and tests for cardiac function (multiple gated acquisition scan/echocardiogram and electrocardiogram) which will be monitored throughout the study.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast Cancer
  • Advanced breast cancer
  • Breast Tumors
  • Cancer of Breast
  • Human Mammary Carcinoma
  • Mammary Neoplasms, Human
  • DOXIL
  • Docetaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females with locally advanced or breast cancer who received prior anthracycline therapy in the or adjuvant setting, and had at least a 12-month disease-free interval since the end of their last cytotoxic therapy, were eligible for the study
  • Participants who received prior hormonal therapy, or no more than 1 cytotoxic chemotherapy regimen (anthracyclines, taxanes, or antitubulin agents were not permitted), or both for advanced disease
  • Participants with normal cardiac function, as evidenced by a normal

Exclusion criteria

Exclusion Criteria:

  • More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer
  • Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel, vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen that included alkylating agents or antimetabolite agents was acceptable)
  • Less than 2 months since the last dose of trastuzumab
  • Less than 3 weeks since last dose of tamoxifen or fulvestrant, or less than 1 week since the last dose of other hormonal therapy
  • Radiation to areas of disease within 30 days before study enrollment
  • History of Class II or greater cardiac disease or other clinical evidence of congestive heart failure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
751 participants (actual)

Study arms

  • Experimental
    DOXIL and docetaxel combination therapy

    DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

    Drug: Docetaxel · Drug: DOXIL

  • Active comparator
    Docetaxel monotherapy

    Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

    Drug: Docetaxel

Interventions

  • Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle

  • DrugDOXIL

    DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.

    Also known as: DOXIL in combination with Docataxel

06

What researchers measure

Primary outcomes

  1. Time to Progression

    Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.

    Time frame: From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled

Secondary outcomes

  1. Overall Survival

    Time interval in months between the date of randomization and the participant's death from any cause.

    Time frame: From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled

  2. Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)

    Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI).

    Time frame: Up to 30 to 42 days after last dose of study medication

07

Results

Posted Oct 2, 2012

Participant flow

A total of 751 participants were enrolled and randomized at 143 sites in 19 countries.

Participant flow — Overall Study
MilestoneDocetaxelDOXIL+Docetaxel
Started373378
Completed45
Not completed369373
Withdrew: Progressive disease220189
Withdrew: Physician decision6158
Withdrew: Withdrawal by subject3846
Withdrew: Adverse event2948
Withdrew: 2cycles therapy beyond complete response916
Withdrew: Death97
Withdrew: Lost to follow-up13
Withdrew: Other26

Outcome measures

SecondaryOverall Survival

Time interval in months between the date of randomization and the participant's death from any cause.

Time frame:
From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled
Reported as:
Median · Months
Overall Survival
MonthsDocetaxelDOXIL+Docetaxel
Overall Survival20.7 (18.3 to 26.3)20.4 (19.0 to 23.1)
Statistical analysis
  • Docetaxel vs DOXIL+Docetaxel · Log Rank · p = 0.5988 (Not adjusted for multiple comparison.) · Hazard ratio (hr): 1.06 · 95% CI 0.86 to 1.3
SecondaryResponse Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)

Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI).

Time frame:
Up to 30 to 42 days after last dose of study medication
Reported as:
Number · Participants
Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)
ParticipantsDocetaxelDOXIL+Docetaxel
Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)95129
Statistical analysis
  • Docetaxel vs DOXIL+Docetaxel · Cochran-Mantel-Haenszel · p = 0.0085 (Not adjusted for multiple comparison)
PrimaryTime to Progression

Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.

Time frame:
From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled
Reported as:
Median · Months
Time to Progression
MonthsDocetaxelDOXIL+Docetaxel
Time to Progression7.0 (5.9 to 7.7)9.8 (8.1 to 10.5)
Statistical analysis
  • Docetaxel vs DOXIL+Docetaxel · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.65 · 95% CI 0.55 to 0.77

Adverse events

Collected over From first dose of study medication until 30 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel—59/373 (15.8%)340/373 (91.2%)
DOXIL+Docetaxel—69/377 (18.3%)359/377 (95.2%)
Most frequent serious events
Showing 10 of 118
Most frequent serious events
EventDocetaxelDOXIL+Docetaxel
NeutropeniaBlood and lymphatic system disorders14/37317/377
PneumoniaInfections and infestations0/37312/377
Febrile neutropeniaBlood and lymphatic system disorders10/37310/377
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders0/3737/377
PyrexiaGeneral disorders3/3736/377
Neutropenic sepsisInfections and infestations4/3730/377
Pleural effusionRespiratory, thoracic and mediastinal disorders4/3730/377
LeukopeniaBlood and lymphatic system disorders1/3734/377
VomitingGastrointestinal disorders3/3734/377
StomatitisGastrointestinal disorders1/3734/377
Most frequent other events
Showing 10 of 32
Most frequent other events
EventDocetaxelDOXIL+Docetaxel
NeutropeniaBlood and lymphatic system disorders241/373244/377
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders5/373229/377
Mucositis/stomatitisGastrointestinal disorders53/373195/377
AlopeciaSkin and subcutaneous tissue disorders169/373181/377
LeukopeniaBlood and lymphatic system disorders99/373126/377
AstheniaGeneral disorders72/373110/377
NauseaGastrointestinal disorders80/373105/377
FatigueGeneral disorders56/37378/377
Peripheral neuropathyNervous system disorders68/37378/377
AnaemiaBlood and lymphatic system disorders62/37375/377

Baseline characteristics

Age, Continuous
Age, Continuous(years)DocetaxelDOXIL+DocetaxelTotal
Mean52.0 ± 9.2352.8 ± 9.1752.4 ± 9.20
Sex: Female, Male
Sex: Female, Male(Participants)DocetaxelDOXIL+DocetaxelTotal
Female373378751
Male000
08

Study locations

151 sites
  • Hoover, Alabama, United States
  • Fountain Valley, California, United States
  • Long Beach, California, United States
  • Los Angeles, California, United States
  • Palm Springs, California, United States
  • Newark, Delaware, United States
  • Lakeland, Florida, United States
  • Fort Gordon, Georgia, United States
  • Centralia, Illinois, United States
  • Joliet, Illinois, United States
  • Indianapolis, Indiana, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Lafayette, Louisiana, United States
  • Baltimore, Maryland, United States
  • Jackson, Mississippi, United States
  • Las Vegas, Nevada, United States
  • Newark, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Bronx, New York, United States
  • Cooperstown, New York, United States
  • New York, New York, United States
  • Gastonia, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Upland, Pennsylvania, United States
  • Providence, Rhode Island, United States
  • Charleston, South Carolina, United States
  • N Charleston, South Carolina, United States
  • Fort Worth, Texas, United States
  • Pasadena, Texas, United States
  • Plovdiv, Bulgaria
  • Shumen, Bulgaria
  • Sofia, Bulgaria
  • Stara Zagora, Bulgaria
  • Varna, Bulgaria
  • Tartu N/A, Estonia
  • Rabat, France
  • Tunis, France
  • Budapest N/A, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
  • Szeged, Hungary
  • Szekesfehervar, Hungary
  • Zalaegerszeg, Hungary
  • Ashkelon, Israel
  • Haifa, Israel
  • Jerusalem, Israel
  • Ramat-Gan, Israel
  • Tel Aviv, Israel
  • Riga, Latvia
  • Kaunas, Lithuania
  • Vilnius, Lithuania
  • Arnhem, Netherlands
  • Capelle Aan Den Ijssel, Netherlands
  • Den Haag, Netherlands
  • Roosendaal, Netherlands
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Bytom, Poland
  • Gdansk, Poland
  • Gdynia N/A, Poland
  • Gliwice, Poland
  • Kielce, Poland
  • Koszalin, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Olsztyn, Poland
  • Poznan, Poland
  • Warsaw, Poland
  • Coimbra, Portugal
  • Matosinhos N/A, Portugal
  • Bacau, Romania
  • Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Hunedoara, Romania
  • Iasi, Romania
  • Onesti, Romania
  • Timisoara, Romania
  • Arkhangelsk, Russian Federation
  • Balashikha, Russian Federation
  • Barnaul, Russian Federation
  • Chelyabinsk, Russian Federation
  • Ekaterinburg, Russian Federation
  • Engels Saratov Region, Russian Federation
  • Irkutsk, Russian Federation
  • Ivanovo, Russian Federation
  • Izhevsk, Russian Federation
  • Kazan, Russian Federation
  • Krasnodar, Russian Federation
  • Leningrad Region, Russian Federation
  • Lipetsk, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow Region, Russian Federation
  • Moscow, Russian Federation
  • Murmansk, Russian Federation
  • N Novgorod N/A, Russian Federation
  • Nizhny Novgorod, Russian Federation
  • Novosibirsk, Russian Federation
  • Obninsk, Russian Federation

Showing the first 100 of 151 sites across 18 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 3 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2004
First posted
Sep 13, 2004
Start
Sep 2004
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Oct 2, 2012
Last update
Apr 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00091442
Responsible party
Sponsor
First posted
Sep 13, 2004
Start date
Sep 2004
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Oct 2, 2012
Last update
Apr 21, 2014

Study contacts

Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
study director · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion